???pagination.result.count???
The plant-derived alkaloid aloperine prevents ischemia/reperfusion injury-induced sudden cardiac death. , Hu Z., FASEB J. July 1, 2023; 37 (7): e22999.
Polyunsaturated fatty acid analogues differentially affect cardiac NaV, CaV, and KV channels through unique mechanisms. , Bohannon BM., Elife. March 24, 2020; 9
Non-sedating antihistamines block G-protein-gated inwardly rectifying K+ channels. , Chen IS., Br J Pharmacol. September 1, 2019; 176 (17): 3161-3179.
The acute effects of hydrocortisone on cardiac electrocardiography, action potentials, intracellular calcium, and contraction: The role of protein kinase C. , Park MH., Mol Cell Endocrinol. August 20, 2019; 494 110488.
Facilitation of IKr current by some hERG channel blockers suppresses early afterdepolarizations. , Furutani K., J Gen Physiol. February 4, 2019; 151 (2): 214-230.
Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are IKr blockers with proarrhythmic effects in vitro and in vivo. , Baburin I., Pharmacol Res. May 1, 2018; 131 150-163.
Regulation of human cardiac potassium channels by full-length KCNE3 and KCNE4. , Abbott GW., Sci Rep. December 6, 2016; 6 38412.
Molecular Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium. , Pedersen PJ., PLoS One. September 4, 2015; 10 (9): e0138320.
Eag Domains Regulate LQT Mutant hERG Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. , Liu QN., PLoS One. April 22, 2015; 10 (4): e0123951.
Concatenated hERG1 tetramers reveal stoichiometry of altered channel gating by RPR-260243. , Wu W., Mol Pharmacol. January 1, 2015; 87 (3): 401-9.
Ginseng gintonin activates the human cardiac delayed rectifier K+ channel: involvement of Ca2+/calmodulin binding sites. , Choi SH., Mol Cells. September 1, 2014; 37 (9): 656-63.
Concerted all-or-none subunit interactions mediate slow deactivation of human ether-à- go-go-related gene K+ channels. , Thomson SJ., J Biol Chem. August 22, 2014; 289 (34): 23428-36.
The variant hERG/R148W associated with LQTS is a mutation that reduces current density on co-expression with the WT. , Mechakra A., Gene. February 25, 2014; 536 (2): 348-56.
Up-regulation of Kir2.1 ( KCNJ2) by the serum & glucocorticoid inducible SGK3. , Munoz C., Cell Physiol Biochem. January 1, 2014; 33 (2): 491-500.
Coxsackievirus B3 modulates cardiac ion channels. , Steinke K., FASEB J. October 1, 2013; 27 (10): 4108-21.
Effect of azelastine on cardiac repolarization of guinea-pig cardiomyocytes, hERG K⁺ channel, and human L-type and T-type Ca²⁺ channel. , Park MH., J Pharmacol Sci. September 20, 2013; 123 (1): 67-77.
External pH modulates EAG superfamily K+ channels through EAG-specific acidic residues in the voltage sensor. , Kazmierczak M., J Gen Physiol. June 1, 2013; 141 (6): 721-35.
Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. , Jehle J., Br J Pharmacol. March 1, 2013; 168 (5): 1215-29.
Block of hERG K+ channel and prolongation of action potential duration by fluphenazine at submicromolar concentration. , Hong HK., Eur J Pharmacol. February 28, 2013; 702 (1-3): 165-73.
Blocking of the human ether-à- go-go-related gene channel by imatinib mesylate. , Dong Q., Biol Pharm Bull. January 1, 2013; 36 (2): 268-75.
Acute alteration of cardiac ECG, action potential, I(Kr) and the human ether-a- go-go-related gene ( hERG) K+ channel by PCB 126 and PCB 77. , Park MH., Toxicol Appl Pharmacol. July 1, 2012; 262 (1): 60-9.
18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels. , Du YM., Acta Pharmacol Sin. June 1, 2012; 33 (6): 752-60.
Effects of the histamine H(1) receptor antagonist hydroxyzine on hERG K(+) channels and cardiac action potential duration. , Lee BH., Acta Pharmacol Sin. September 1, 2011; 32 (9): 1128-37.
hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. , Staudacher I., Naunyn Schmiedebergs Arch Pharmacol. February 1, 2011; 383 (2): 119-39.
Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels. , Larsen AP., Br J Pharmacol. October 1, 2010; 161 (3): 614-28.
Response of i(kr) and HERG currents to the antipsychotics tiapride and sulpiride. , Jo SH., Korean J Physiol Pharmacol. October 1, 2010; 14 (5): 305-10.
Differential expression of hERG1 channel isoforms reproduces properties of native I(Kr) and modulates cardiac action potential characteristics. , Larsen AP., PLoS One. February 2, 2010; 5 (2): e9021.
H(1) antihistamine drug promethazine directly blocks hERG K(+) channel. , Jo SH., Pharmacol Res. November 1, 2009; 60 (5): 429-37.
Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. , Scherer D., Br J Pharmacol. January 1, 2009; 156 (2): 226-36.
Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration. , Kim YJ., J Cardiovasc Pharmacol. December 1, 2008; 52 (6): 485-93.
Characterization of hERG1a and hERG1b potassium channels-a possible role for hERG1b in the I (Kr) current. , Larsen AP., Pflugers Arch. September 1, 2008; 456 (6): 1137-48.
Chlorthalidone inhibits the KvLQT1 potassium current in guinea-pig ventricular myocytes and oocytes from Xenopus laevis. , Mancilla-Simbro C., Br J Pharmacol. February 1, 2008; 153 (3): 448-58.
Extracellular acidification and hyperkalemia induce changes in HERG inhibition by ibutilide. , Lin C., Cardiology. January 1, 2008; 110 (3): 209-16.
Molecular interaction of droperidol with human ether-a- go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization. , Schwoerer AP., Anesthesiology. May 1, 2007; 106 (5): 967-76.
Upregulation of KCNE1 induces QT interval prolongation in patients with chronic heart failure. , Watanabe E., Circ J. April 1, 2007; 71 (4): 471-8.
Inhibitory effects of coronary vasodilator papaverine on heterologously-expressed HERG currents in Xenopus oocytes. , Kim CS., Acta Pharmacol Sin. April 1, 2007; 28 (4): 503-10.
The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. , Lin C., Cardiology. January 1, 2007; 108 (1): 18-27.
The effects of quinidine and its chiral isolates on erg-1sm potassium current and correlation with gastrointestinal augmentation. , Cvetanovic I., Am J Ther. January 1, 2007; 14 (3): 269-76.
Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. , Hansen RS., Mol Pharmacol. October 1, 2006; 70 (4): 1319-29.
Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine. , Kim MD ., Eur J Pharmacol. August 21, 2006; 544 (1-3): 82-90.
Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. , Lee SY., Br J Pharmacol. June 1, 2006; 148 (4): 499-509.
Frequency-dependent modulation of KCNQ1 and HERG1 potassium channels. , Diness TG., Biochem Biophys Res Commun. May 19, 2006; 343 (4): 1224-33.
Activation of human ether-a- go-go-related gene potassium channels by the diphenylurea 1,3- bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). , Hansen RS., Mol Pharmacol. January 1, 2006; 69 (1): 266-77.
In vivo targeting of ERG potassium channels in mice and dogs by a positron-emitting analogue of fluoroclofilium. , Kim SW., Exp Mol Med. August 31, 2005; 37 (4): 269-75.
Inhibition of human ether-a- go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine. , Choi SY., J Pharmacol Exp Ther. May 1, 2005; 313 (2): 888-95.
Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action. , Kiesecker C., Naunyn Schmiedebergs Arch Pharmacol. December 1, 2004; 370 (6): 423-35.
Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X). , Thomas D., Cardiovasc Res. December 1, 2004; 64 (3): 467-76.
Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. , Gögelein H., Naunyn Schmiedebergs Arch Pharmacol. September 1, 2004; 370 (3): 183-92.
Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. , Schram G., Br J Pharmacol. August 1, 2004; 142 (8): 1300-8.
Activation properties of Kv4.3 channels: time, voltage and [K+]o dependence. , Wang S., J Physiol. June 15, 2004; 557 (Pt 3): 705-17.